Clinical trial
A Phase 2a Randomized, Double-Blind Study to Evaluate the Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07688239 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Randomized, Double-Blind Study to Evaluate the Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Tiziana Life Sciences LTD
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- July 25, 2026
- Completion date
- November 30, 2027
- Enrollment
- 44 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
als, als (amyotrophic lateral sclerosis), als - amyotrophic lateral sclerosis